A clinical-stage gene therapy company developing one-time treatments for rare brain and nervous-system diseases. Founded in 2019 as a spinout of the University of Pennsylvania's Gene Therapy Program, it builds on the work of gene-therapy pioneer James Wilson. Its name comes from "passaging" — the lab process of growing and purifying the harmless viruses that carry therapeutic genes into cells. Its lead programs target rare disorders such as GM1 gangliosidosis and Krabbe disease.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +1.09M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.